nodes	percent_of_prediction	percent_of_DWPC	metapath
Ondansetron—SLC47A2—Mitoxantrone—lymphatic system cancer	0.449	0.521	CbGbCtD
Ondansetron—SLC47A1—Mitoxantrone—lymphatic system cancer	0.187	0.216	CbGbCtD
Ondansetron—CYP1A2—Carmustine—lymphatic system cancer	0.0374	0.0434	CbGbCtD
Ondansetron—CYP3A5—Teniposide—lymphatic system cancer	0.0337	0.0392	CbGbCtD
Ondansetron—CYP2E1—Mitoxantrone—lymphatic system cancer	0.0304	0.0353	CbGbCtD
Ondansetron—CYP2C9—Teniposide—lymphatic system cancer	0.0226	0.0263	CbGbCtD
Ondansetron—CYP3A7—Vincristine—lymphatic system cancer	0.0217	0.0251	CbGbCtD
Ondansetron—CYP3A7-CYP3A51P—Vincristine—lymphatic system cancer	0.0217	0.0251	CbGbCtD
Ondansetron—CYP3A5—Vincristine—lymphatic system cancer	0.0162	0.0189	CbGbCtD
Ondansetron—CYP3A4—Cytarabine—lymphatic system cancer	0.0134	0.0155	CbGbCtD
Ondansetron—CYP3A4—Teniposide—lymphatic system cancer	0.0132	0.0153	CbGbCtD
Ondansetron—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0092	0.0107	CbGbCtD
Ondansetron—CYP3A4—Vincristine—lymphatic system cancer	0.00633	0.00735	CbGbCtD
Ondansetron—Swelling—Carmustine—lymphatic system cancer	0.000691	0.005	CcSEcCtD
Ondansetron—Chills—Teniposide—lymphatic system cancer	0.000673	0.00486	CcSEcCtD
Ondansetron—Arrhythmia—Teniposide—lymphatic system cancer	0.00067	0.00484	CcSEcCtD
Ondansetron—Haemoglobin—Fludarabine—lymphatic system cancer	0.000663	0.00479	CcSEcCtD
Ondansetron—Haemorrhage—Fludarabine—lymphatic system cancer	0.000659	0.00476	CcSEcCtD
Ondansetron—Hepatic failure—Vincristine—lymphatic system cancer	0.000648	0.00468	CcSEcCtD
Ondansetron—Swelling—Mitoxantrone—lymphatic system cancer	0.000643	0.00464	CcSEcCtD
Ondansetron—Visual impairment—Fludarabine—lymphatic system cancer	0.000635	0.00459	CcSEcCtD
Ondansetron—Erythema multiforme—Fludarabine—lymphatic system cancer	0.000623	0.0045	CcSEcCtD
Ondansetron—Hypoxia—Methotrexate—lymphatic system cancer	0.000613	0.00443	CcSEcCtD
Ondansetron—Agitation—Teniposide—lymphatic system cancer	0.0006	0.00434	CcSEcCtD
Ondansetron—Bronchospasm—Bleomycin—lymphatic system cancer	0.000594	0.00429	CcSEcCtD
Ondansetron—Chills—Fludarabine—lymphatic system cancer	0.000592	0.00428	CcSEcCtD
Ondansetron—Arrhythmia—Fludarabine—lymphatic system cancer	0.000589	0.00426	CcSEcCtD
Ondansetron—Anaphylactoid reaction—Mitoxantrone—lymphatic system cancer	0.000586	0.00423	CcSEcCtD
Ondansetron—Liver disorder—Methotrexate—lymphatic system cancer	0.000571	0.00413	CcSEcCtD
Ondansetron—Liver function test abnormal—Carmustine—lymphatic system cancer	0.000563	0.00407	CcSEcCtD
Ondansetron—Chest pain—Teniposide—lymphatic system cancer	0.000556	0.00402	CcSEcCtD
Ondansetron—Hypokalaemia—Carmustine—lymphatic system cancer	0.000555	0.00401	CcSEcCtD
Ondansetron—Urinary retention—Vincristine—lymphatic system cancer	0.000554	0.004	CcSEcCtD
Ondansetron—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.000533	0.00385	CcSEcCtD
Ondansetron—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.000533	0.00385	CcSEcCtD
Ondansetron—Acute coronary syndrome—Bleomycin—lymphatic system cancer	0.000531	0.00384	CcSEcCtD
Ondansetron—Myocardial infarction—Bleomycin—lymphatic system cancer	0.000528	0.00381	CcSEcCtD
Ondansetron—Agitation—Fludarabine—lymphatic system cancer	0.000527	0.00381	CcSEcCtD
Ondansetron—Aspartate aminotransferase increased—Vincristine—lymphatic system cancer	0.000524	0.00379	CcSEcCtD
Ondansetron—Tachycardia—Teniposide—lymphatic system cancer	0.00052	0.00376	CcSEcCtD
Ondansetron—Malaise—Fludarabine—lymphatic system cancer	0.000518	0.00374	CcSEcCtD
Ondansetron—Hypokalaemia—Mitoxantrone—lymphatic system cancer	0.000516	0.00373	CcSEcCtD
Ondansetron—Pruritus—Mechlorethamine—lymphatic system cancer	0.000511	0.0037	CcSEcCtD
Ondansetron—Aspartate aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.000511	0.00369	CcSEcCtD
Ondansetron—Cough—Fludarabine—lymphatic system cancer	0.000501	0.00362	CcSEcCtD
Ondansetron—Hypotension—Teniposide—lymphatic system cancer	0.000498	0.0036	CcSEcCtD
Ondansetron—Convulsion—Fludarabine—lymphatic system cancer	0.000497	0.00359	CcSEcCtD
Ondansetron—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.000495	0.00357	CcSEcCtD
Ondansetron—Haemoglobin—Bleomycin—lymphatic system cancer	0.000486	0.00351	CcSEcCtD
Ondansetron—Haemorrhage—Bleomycin—lymphatic system cancer	0.000483	0.00349	CcSEcCtD
Ondansetron—Discomfort—Fludarabine—lymphatic system cancer	0.000483	0.00349	CcSEcCtD
Ondansetron—Dyspnoea—Teniposide—lymphatic system cancer	0.000475	0.00343	CcSEcCtD
Ondansetron—Dysuria—Vincristine—lymphatic system cancer	0.000471	0.0034	CcSEcCtD
Ondansetron—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.000468	0.00339	CcSEcCtD
Ondansetron—Vomiting—Mechlorethamine—lymphatic system cancer	0.00046	0.00332	CcSEcCtD
Ondansetron—Nervous system disorder—Fludarabine—lymphatic system cancer	0.000459	0.00332	CcSEcCtD
Ondansetron—Urinary tract infection—Carmustine—lymphatic system cancer	0.000457	0.0033	CcSEcCtD
Ondansetron—Rash—Mechlorethamine—lymphatic system cancer	0.000456	0.00329	CcSEcCtD
Ondansetron—Dermatitis—Mechlorethamine—lymphatic system cancer	0.000455	0.00329	CcSEcCtD
Ondansetron—Flushing—Bleomycin—lymphatic system cancer	0.000449	0.00324	CcSEcCtD
Ondansetron—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.000442	0.0032	CcSEcCtD
Ondansetron—Myocardial infarction—Vincristine—lymphatic system cancer	0.00044	0.00318	CcSEcCtD
Ondansetron—Feeling abnormal—Teniposide—lymphatic system cancer	0.000439	0.00317	CcSEcCtD
Ondansetron—Drowsiness—Mitoxantrone—lymphatic system cancer	0.000437	0.00316	CcSEcCtD
Ondansetron—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.000436	0.00315	CcSEcCtD
Ondansetron—Chills—Bleomycin—lymphatic system cancer	0.000434	0.00313	CcSEcCtD
Ondansetron—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.000431	0.00311	CcSEcCtD
Ondansetron—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.000428	0.0031	CcSEcCtD
Ondansetron—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.000425	0.00307	CcSEcCtD
Ondansetron—Haemoglobin—Carmustine—lymphatic system cancer	0.000424	0.00306	CcSEcCtD
Ondansetron—Urticaria—Teniposide—lymphatic system cancer	0.000423	0.00306	CcSEcCtD
Ondansetron—Haemorrhage—Carmustine—lymphatic system cancer	0.000422	0.00305	CcSEcCtD
Ondansetron—Abdominal pain—Teniposide—lymphatic system cancer	0.000421	0.00304	CcSEcCtD
Ondansetron—Body temperature increased—Teniposide—lymphatic system cancer	0.000421	0.00304	CcSEcCtD
Ondansetron—Erythema—Bleomycin—lymphatic system cancer	0.000421	0.00304	CcSEcCtD
Ondansetron—Paraesthesia—Fludarabine—lymphatic system cancer	0.000421	0.00304	CcSEcCtD
Ondansetron—Dyspnoea—Fludarabine—lymphatic system cancer	0.000418	0.00302	CcSEcCtD
Ondansetron—Visual impairment—Carmustine—lymphatic system cancer	0.000407	0.00294	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.000404	0.00292	CcSEcCtD
Ondansetron—Fatigue—Fludarabine—lymphatic system cancer	0.000404	0.00292	CcSEcCtD
Ondansetron—Constipation—Fludarabine—lymphatic system cancer	0.000401	0.00289	CcSEcCtD
Ondansetron—Pain—Fludarabine—lymphatic system cancer	0.000401	0.00289	CcSEcCtD
Ondansetron—Bradycardia—Mitoxantrone—lymphatic system cancer	0.000399	0.00289	CcSEcCtD
Ondansetron—Eye disorder—Carmustine—lymphatic system cancer	0.000394	0.00285	CcSEcCtD
Ondansetron—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.000394	0.00285	CcSEcCtD
Ondansetron—Hypersensitivity—Teniposide—lymphatic system cancer	0.000393	0.00284	CcSEcCtD
Ondansetron—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.000392	0.00283	CcSEcCtD
Ondansetron—Flushing—Carmustine—lymphatic system cancer	0.000392	0.00283	CcSEcCtD
Ondansetron—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00039	0.00282	CcSEcCtD
Ondansetron—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000386	0.00279	CcSEcCtD
Ondansetron—Asthenia—Teniposide—lymphatic system cancer	0.000382	0.00276	CcSEcCtD
Ondansetron—Malaise—Bleomycin—lymphatic system cancer	0.000379	0.00274	CcSEcCtD
Ondansetron—Pruritus—Teniposide—lymphatic system cancer	0.000377	0.00272	CcSEcCtD
Ondansetron—Arrhythmia—Carmustine—lymphatic system cancer	0.000377	0.00272	CcSEcCtD
Ondansetron—Cardiac disorder—Vincristine—lymphatic system cancer	0.000374	0.0027	CcSEcCtD
Ondansetron—Body temperature increased—Fludarabine—lymphatic system cancer	0.00037	0.00268	CcSEcCtD
Ondansetron—Erythema—Carmustine—lymphatic system cancer	0.000367	0.00265	CcSEcCtD
Ondansetron—Cough—Bleomycin—lymphatic system cancer	0.000367	0.00265	CcSEcCtD
Ondansetron—Angiopathy—Vincristine—lymphatic system cancer	0.000365	0.00264	CcSEcCtD
Ondansetron—Diarrhoea—Teniposide—lymphatic system cancer	0.000365	0.00264	CcSEcCtD
Ondansetron—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000363	0.00262	CcSEcCtD
Ondansetron—Chest pain—Bleomycin—lymphatic system cancer	0.000358	0.00259	CcSEcCtD
Ondansetron—Discomfort—Bleomycin—lymphatic system cancer	0.000354	0.00256	CcSEcCtD
Ondansetron—Chills—Mitoxantrone—lymphatic system cancer	0.000352	0.00254	CcSEcCtD
Ondansetron—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00035	0.00253	CcSEcCtD
Ondansetron—Vision blurred—Carmustine—lymphatic system cancer	0.000346	0.0025	CcSEcCtD
Ondansetron—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000345	0.00249	CcSEcCtD
Ondansetron—Tremor—Carmustine—lymphatic system cancer	0.000344	0.00249	CcSEcCtD
Ondansetron—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000343	0.00248	CcSEcCtD
Ondansetron—Erythema—Mitoxantrone—lymphatic system cancer	0.000341	0.00247	CcSEcCtD
Ondansetron—Vomiting—Teniposide—lymphatic system cancer	0.000339	0.00245	CcSEcCtD
Ondansetron—Agitation—Carmustine—lymphatic system cancer	0.000338	0.00244	CcSEcCtD
Ondansetron—Asthenia—Fludarabine—lymphatic system cancer	0.000336	0.00243	CcSEcCtD
Ondansetron—Rash—Teniposide—lymphatic system cancer	0.000336	0.00243	CcSEcCtD
Ondansetron—Dermatitis—Teniposide—lymphatic system cancer	0.000336	0.00243	CcSEcCtD
Ondansetron—Headache—Teniposide—lymphatic system cancer	0.000334	0.00241	CcSEcCtD
Ondansetron—Pruritus—Fludarabine—lymphatic system cancer	0.000331	0.00239	CcSEcCtD
Ondansetron—Agitation—Vincristine—lymphatic system cancer	0.000322	0.00233	CcSEcCtD
Ondansetron—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000322	0.00233	CcSEcCtD
Ondansetron—Hypotension—Bleomycin—lymphatic system cancer	0.000321	0.00232	CcSEcCtD
Ondansetron—Diarrhoea—Fludarabine—lymphatic system cancer	0.00032	0.00232	CcSEcCtD
Ondansetron—Convulsion—Carmustine—lymphatic system cancer	0.000318	0.0023	CcSEcCtD
Ondansetron—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000317	0.00229	CcSEcCtD
Ondansetron—Hepatic failure—Methotrexate—lymphatic system cancer	0.000314	0.00227	CcSEcCtD
Ondansetron—Chest pain—Carmustine—lymphatic system cancer	0.000313	0.00226	CcSEcCtD
Ondansetron—Anxiety—Carmustine—lymphatic system cancer	0.000312	0.00225	CcSEcCtD
Ondansetron—Paraesthesia—Bleomycin—lymphatic system cancer	0.000308	0.00223	CcSEcCtD
Ondansetron—Malaise—Mitoxantrone—lymphatic system cancer	0.000308	0.00223	CcSEcCtD
Ondansetron—Dyspnoea—Bleomycin—lymphatic system cancer	0.000306	0.00221	CcSEcCtD
Ondansetron—Convulsion—Vincristine—lymphatic system cancer	0.000304	0.0022	CcSEcCtD
Ondansetron—Visual disturbance—Methotrexate—lymphatic system cancer	0.000298	0.00215	CcSEcCtD
Ondansetron—Cough—Mitoxantrone—lymphatic system cancer	0.000298	0.00215	CcSEcCtD
Ondansetron—Vomiting—Fludarabine—lymphatic system cancer	0.000298	0.00215	CcSEcCtD
Ondansetron—Convulsion—Mitoxantrone—lymphatic system cancer	0.000296	0.00214	CcSEcCtD
Ondansetron—Rash—Fludarabine—lymphatic system cancer	0.000295	0.00213	CcSEcCtD
Ondansetron—Dermatitis—Fludarabine—lymphatic system cancer	0.000295	0.00213	CcSEcCtD
Ondansetron—Pain—Bleomycin—lymphatic system cancer	0.000294	0.00212	CcSEcCtD
Ondansetron—Headache—Fludarabine—lymphatic system cancer	0.000293	0.00212	CcSEcCtD
Ondansetron—Tachycardia—Carmustine—lymphatic system cancer	0.000293	0.00211	CcSEcCtD
Ondansetron—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.000292	0.00211	CcSEcCtD
Ondansetron—Chest pain—Mitoxantrone—lymphatic system cancer	0.000291	0.0021	CcSEcCtD
Ondansetron—Anxiety—Mitoxantrone—lymphatic system cancer	0.00029	0.00209	CcSEcCtD
Ondansetron—Discomfort—Mitoxantrone—lymphatic system cancer	0.000287	0.00208	CcSEcCtD
Ondansetron—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000286	0.00207	CcSEcCtD
Ondansetron—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000283	0.00205	CcSEcCtD
Ondansetron—Nervous system disorder—Vincristine—lymphatic system cancer	0.000281	0.00203	CcSEcCtD
Ondansetron—Hypotension—Carmustine—lymphatic system cancer	0.00028	0.00202	CcSEcCtD
Ondansetron—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000279	0.00201	CcSEcCtD
Ondansetron—Shock—Mitoxantrone—lymphatic system cancer	0.000274	0.00198	CcSEcCtD
Ondansetron—Urticaria—Bleomycin—lymphatic system cancer	0.000273	0.00197	CcSEcCtD
Ondansetron—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000272	0.00197	CcSEcCtD
Ondansetron—Body temperature increased—Bleomycin—lymphatic system cancer	0.000271	0.00196	CcSEcCtD
Ondansetron—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000271	0.00196	CcSEcCtD
Ondansetron—Paraesthesia—Carmustine—lymphatic system cancer	0.000269	0.00195	CcSEcCtD
Ondansetron—Hypotension—Vincristine—lymphatic system cancer	0.000267	0.00193	CcSEcCtD
Ondansetron—Dyspnoea—Carmustine—lymphatic system cancer	0.000267	0.00193	CcSEcCtD
Ondansetron—Somnolence—Carmustine—lymphatic system cancer	0.000267	0.00193	CcSEcCtD
Ondansetron—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000261	0.00188	CcSEcCtD
Ondansetron—Hypotension—Mitoxantrone—lymphatic system cancer	0.00026	0.00188	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000259	0.00187	CcSEcCtD
Ondansetron—Paraesthesia—Vincristine—lymphatic system cancer	0.000257	0.00186	CcSEcCtD
Ondansetron—Constipation—Carmustine—lymphatic system cancer	0.000256	0.00185	CcSEcCtD
Ondansetron—Pain—Carmustine—lymphatic system cancer	0.000256	0.00185	CcSEcCtD
Ondansetron—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000254	0.00184	CcSEcCtD
Ondansetron—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000253	0.00183	CcSEcCtD
Ondansetron—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00025	0.00181	CcSEcCtD
Ondansetron—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000248	0.0018	CcSEcCtD
Ondansetron—Somnolence—Mitoxantrone—lymphatic system cancer	0.000248	0.00179	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000247	0.00179	CcSEcCtD
Ondansetron—Feeling abnormal—Carmustine—lymphatic system cancer	0.000247	0.00179	CcSEcCtD
Ondansetron—Fatigue—Vincristine—lymphatic system cancer	0.000247	0.00178	CcSEcCtD
Ondansetron—Asthenia—Bleomycin—lymphatic system cancer	0.000246	0.00178	CcSEcCtD
Ondansetron—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000245	0.00177	CcSEcCtD
Ondansetron—Pain—Vincristine—lymphatic system cancer	0.000245	0.00177	CcSEcCtD
Ondansetron—Constipation—Vincristine—lymphatic system cancer	0.000245	0.00177	CcSEcCtD
Ondansetron—Asthma—Methotrexate—lymphatic system cancer	0.000244	0.00176	CcSEcCtD
Ondansetron—Pruritus—Bleomycin—lymphatic system cancer	0.000243	0.00176	CcSEcCtD
Ondansetron—Fatigue—Mitoxantrone—lymphatic system cancer	0.00024	0.00174	CcSEcCtD
Ondansetron—Pain—Mitoxantrone—lymphatic system cancer	0.000238	0.00172	CcSEcCtD
Ondansetron—Constipation—Mitoxantrone—lymphatic system cancer	0.000238	0.00172	CcSEcCtD
Ondansetron—Abdominal pain—Carmustine—lymphatic system cancer	0.000237	0.00171	CcSEcCtD
Ondansetron—Body temperature increased—Carmustine—lymphatic system cancer	0.000237	0.00171	CcSEcCtD
Ondansetron—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000234	0.00169	CcSEcCtD
Ondansetron—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00023	0.00166	CcSEcCtD
Ondansetron—Dysuria—Methotrexate—lymphatic system cancer	0.000228	0.00165	CcSEcCtD
Ondansetron—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000228	0.00165	CcSEcCtD
Ondansetron—Body temperature increased—Vincristine—lymphatic system cancer	0.000226	0.00163	CcSEcCtD
Ondansetron—Abdominal pain—Vincristine—lymphatic system cancer	0.000226	0.00163	CcSEcCtD
Ondansetron—Urticaria—Mitoxantrone—lymphatic system cancer	0.000221	0.0016	CcSEcCtD
Ondansetron—Hypersensitivity—Carmustine—lymphatic system cancer	0.000221	0.0016	CcSEcCtD
Ondansetron—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00022	0.00159	CcSEcCtD
Ondansetron—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00022	0.00159	CcSEcCtD
Ondansetron—Vomiting—Bleomycin—lymphatic system cancer	0.000218	0.00158	CcSEcCtD
Ondansetron—Drowsiness—Methotrexate—lymphatic system cancer	0.000218	0.00157	CcSEcCtD
Ondansetron—Rash—Bleomycin—lymphatic system cancer	0.000217	0.00156	CcSEcCtD
Ondansetron—Dermatitis—Bleomycin—lymphatic system cancer	0.000216	0.00156	CcSEcCtD
Ondansetron—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000216	0.00156	CcSEcCtD
Ondansetron—Asthenia—Carmustine—lymphatic system cancer	0.000215	0.00155	CcSEcCtD
Ondansetron—Hypersensitivity—Vincristine—lymphatic system cancer	0.000211	0.00152	CcSEcCtD
Ondansetron—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000206	0.00149	CcSEcCtD
Ondansetron—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000205	0.00148	CcSEcCtD
Ondansetron—Asthenia—Vincristine—lymphatic system cancer	0.000205	0.00148	CcSEcCtD
Ondansetron—Diarrhoea—Carmustine—lymphatic system cancer	0.000205	0.00148	CcSEcCtD
Ondansetron—Asthenia—Mitoxantrone—lymphatic system cancer	0.0002	0.00145	CcSEcCtD
Ondansetron—Dizziness—Carmustine—lymphatic system cancer	0.000198	0.00143	CcSEcCtD
Ondansetron—Haemoglobin—Methotrexate—lymphatic system cancer	0.000196	0.00142	CcSEcCtD
Ondansetron—Diarrhoea—Vincristine—lymphatic system cancer	0.000196	0.00141	CcSEcCtD
Ondansetron—Haemorrhage—Methotrexate—lymphatic system cancer	0.000195	0.00141	CcSEcCtD
Ondansetron—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000191	0.00138	CcSEcCtD
Ondansetron—Vomiting—Carmustine—lymphatic system cancer	0.000191	0.00138	CcSEcCtD
Ondansetron—Dizziness—Vincristine—lymphatic system cancer	0.000189	0.00137	CcSEcCtD
Ondansetron—Rash—Carmustine—lymphatic system cancer	0.000189	0.00137	CcSEcCtD
Ondansetron—Dermatitis—Carmustine—lymphatic system cancer	0.000189	0.00136	CcSEcCtD
Ondansetron—Visual impairment—Methotrexate—lymphatic system cancer	0.000188	0.00136	CcSEcCtD
Ondansetron—Headache—Carmustine—lymphatic system cancer	0.000188	0.00136	CcSEcCtD
Ondansetron—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000185	0.00134	CcSEcCtD
Ondansetron—Eye disorder—Methotrexate—lymphatic system cancer	0.000183	0.00132	CcSEcCtD
Ondansetron—Vomiting—Vincristine—lymphatic system cancer	0.000182	0.00131	CcSEcCtD
Ondansetron—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000181	0.00131	CcSEcCtD
Ondansetron—Rash—Vincristine—lymphatic system cancer	0.00018	0.0013	CcSEcCtD
Ondansetron—Dermatitis—Vincristine—lymphatic system cancer	0.00018	0.0013	CcSEcCtD
Ondansetron—Headache—Vincristine—lymphatic system cancer	0.000179	0.0013	CcSEcCtD
Ondansetron—Angiopathy—Methotrexate—lymphatic system cancer	0.000177	0.00128	CcSEcCtD
Ondansetron—Vomiting—Mitoxantrone—lymphatic system cancer	0.000177	0.00128	CcSEcCtD
Ondansetron—Immune system disorder—Methotrexate—lymphatic system cancer	0.000177	0.00128	CcSEcCtD
Ondansetron—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000176	0.00127	CcSEcCtD
Ondansetron—Rash—Mitoxantrone—lymphatic system cancer	0.000176	0.00127	CcSEcCtD
Ondansetron—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000176	0.00127	CcSEcCtD
Ondansetron—Chills—Methotrexate—lymphatic system cancer	0.000175	0.00127	CcSEcCtD
Ondansetron—Headache—Mitoxantrone—lymphatic system cancer	0.000175	0.00126	CcSEcCtD
Ondansetron—Erythema—Methotrexate—lymphatic system cancer	0.00017	0.00123	CcSEcCtD
Ondansetron—Vision blurred—Methotrexate—lymphatic system cancer	0.00016	0.00116	CcSEcCtD
Ondansetron—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000158	0.00114	CcSEcCtD
Ondansetron—Malaise—Methotrexate—lymphatic system cancer	0.000153	0.00111	CcSEcCtD
Ondansetron—Cough—Methotrexate—lymphatic system cancer	0.000148	0.00107	CcSEcCtD
Ondansetron—Convulsion—Methotrexate—lymphatic system cancer	0.000147	0.00107	CcSEcCtD
Ondansetron—Chest pain—Methotrexate—lymphatic system cancer	0.000145	0.00105	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000144	0.00104	CcSEcCtD
Ondansetron—Discomfort—Methotrexate—lymphatic system cancer	0.000143	0.00103	CcSEcCtD
Ondansetron—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000139	0.001	CcSEcCtD
Ondansetron—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000136	0.000984	CcSEcCtD
Ondansetron—Skin disorder—Methotrexate—lymphatic system cancer	0.000135	0.000975	CcSEcCtD
Ondansetron—Hypotension—Methotrexate—lymphatic system cancer	0.00013	0.000938	CcSEcCtD
Ondansetron—Paraesthesia—Methotrexate—lymphatic system cancer	0.000125	0.000901	CcSEcCtD
Ondansetron—Dyspnoea—Methotrexate—lymphatic system cancer	0.000124	0.000895	CcSEcCtD
Ondansetron—Somnolence—Methotrexate—lymphatic system cancer	0.000123	0.000892	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00012	0.000866	CcSEcCtD
Ondansetron—Fatigue—Methotrexate—lymphatic system cancer	0.00012	0.000865	CcSEcCtD
Ondansetron—Pain—Methotrexate—lymphatic system cancer	0.000119	0.000858	CcSEcCtD
Ondansetron—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000114	0.000827	CcSEcCtD
Ondansetron—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000114	0.000821	CcSEcCtD
Ondansetron—Urticaria—Methotrexate—lymphatic system cancer	0.00011	0.000797	CcSEcCtD
Ondansetron—Abdominal pain—Methotrexate—lymphatic system cancer	0.00011	0.000793	CcSEcCtD
Ondansetron—Body temperature increased—Methotrexate—lymphatic system cancer	0.00011	0.000793	CcSEcCtD
Ondansetron—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000102	0.000739	CcSEcCtD
Ondansetron—Asthenia—Methotrexate—lymphatic system cancer	9.96e-05	0.00072	CcSEcCtD
Ondansetron—Pruritus—Methotrexate—lymphatic system cancer	9.82e-05	0.00071	CcSEcCtD
Ondansetron—Diarrhoea—Methotrexate—lymphatic system cancer	9.5e-05	0.000687	CcSEcCtD
Ondansetron—Dizziness—Methotrexate—lymphatic system cancer	9.18e-05	0.000664	CcSEcCtD
Ondansetron—Vomiting—Methotrexate—lymphatic system cancer	8.83e-05	0.000638	CcSEcCtD
Ondansetron—Rash—Methotrexate—lymphatic system cancer	8.76e-05	0.000633	CcSEcCtD
Ondansetron—Dermatitis—Methotrexate—lymphatic system cancer	8.75e-05	0.000632	CcSEcCtD
Ondansetron—Headache—Methotrexate—lymphatic system cancer	8.7e-05	0.000629	CcSEcCtD
